| Dr Andrew B Beaver, MD | |
|
3 Cooper Plz, Suite 408, Camden, NJ 08103-1438 | |
| (856) 968-3670 | |
| (856) 968-8588 |
| Full Name | Dr Andrew B Beaver |
|---|---|
| Gender | Male |
| Speciality | Orthopedic Surgery |
| Experience | 25 Years |
| Location | 3 Cooper Plz, Camden, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1336356021 | NPI | - | NPPES |
| MA08983100 | Other | NJ | STATE LICENSE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207X00000X | Orthopaedic Surgery | MD430687 (Pennsylvania) | Secondary |
| 207X00000X | Orthopaedic Surgery | MA08983100 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mercy Home Health | Springfield, PA | Home health agency |
| Albert Einstein Medical Center | Philadelphia, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Einstein Practice Plan Inc | 2769395896 | 591 |
| St Joseph Medical Group | 3779688650 | 171 |
News Archive
CytoDyn Inc. ("CytoDyn") (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, today announced that CytoDyn Chief Medical Officer David Feigal, M.D., has submitted a revised protocol to the U.S. Food and Drug Administration relating to an upcoming Phase IIb clinical trial of PRO 140, CytoDyn's leading product under development as a treatment for Human Immunodeficiency Virus (HIV) infection.
A new study in the American Journal of Preventive Medicine, published by Elsevier, demonstrated that employees at a large urban hospital who purchased the least healthy food in its cafeteria were more likely to have an unhealthy diet outside of work, be overweight and/or obese, and have risk factors for diabetes and cardiovascular disease, compared to employees who made healthier purchases.
A Fred Hutchinson Cancer Research Center-led study has found that two organochlorine pesticides are associated with an increased risk of endometriosis, a condition that affects up to 10 percent of reproductive-age women.
Pain is a common symptom of cancer and side effect of cancer treatment, and treating cancer-related pain is often a challenge for health care providers.
› Verified 4 days ago
| Entity Name | Einstein Practice Plan Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760434468 PECOS PAC ID: 2769395896 Enrollment ID: O20040219000728 |
News Archive
CytoDyn Inc. ("CytoDyn") (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, today announced that CytoDyn Chief Medical Officer David Feigal, M.D., has submitted a revised protocol to the U.S. Food and Drug Administration relating to an upcoming Phase IIb clinical trial of PRO 140, CytoDyn's leading product under development as a treatment for Human Immunodeficiency Virus (HIV) infection.
A new study in the American Journal of Preventive Medicine, published by Elsevier, demonstrated that employees at a large urban hospital who purchased the least healthy food in its cafeteria were more likely to have an unhealthy diet outside of work, be overweight and/or obese, and have risk factors for diabetes and cardiovascular disease, compared to employees who made healthier purchases.
A Fred Hutchinson Cancer Research Center-led study has found that two organochlorine pesticides are associated with an increased risk of endometriosis, a condition that affects up to 10 percent of reproductive-age women.
Pain is a common symptom of cancer and side effect of cancer treatment, and treating cancer-related pain is often a challenge for health care providers.
› Verified 4 days ago
| Entity Name | Cooper Surgical Associates, Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649217514 PECOS PAC ID: 3274430764 Enrollment ID: O20040405000944 |
News Archive
CytoDyn Inc. ("CytoDyn") (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, today announced that CytoDyn Chief Medical Officer David Feigal, M.D., has submitted a revised protocol to the U.S. Food and Drug Administration relating to an upcoming Phase IIb clinical trial of PRO 140, CytoDyn's leading product under development as a treatment for Human Immunodeficiency Virus (HIV) infection.
A new study in the American Journal of Preventive Medicine, published by Elsevier, demonstrated that employees at a large urban hospital who purchased the least healthy food in its cafeteria were more likely to have an unhealthy diet outside of work, be overweight and/or obese, and have risk factors for diabetes and cardiovascular disease, compared to employees who made healthier purchases.
A Fred Hutchinson Cancer Research Center-led study has found that two organochlorine pesticides are associated with an increased risk of endometriosis, a condition that affects up to 10 percent of reproductive-age women.
Pain is a common symptom of cancer and side effect of cancer treatment, and treating cancer-related pain is often a challenge for health care providers.
› Verified 4 days ago
| Entity Name | St Joseph Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184754657 PECOS PAC ID: 3779688650 Enrollment ID: O20070421000011 |
News Archive
CytoDyn Inc. ("CytoDyn") (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, today announced that CytoDyn Chief Medical Officer David Feigal, M.D., has submitted a revised protocol to the U.S. Food and Drug Administration relating to an upcoming Phase IIb clinical trial of PRO 140, CytoDyn's leading product under development as a treatment for Human Immunodeficiency Virus (HIV) infection.
A new study in the American Journal of Preventive Medicine, published by Elsevier, demonstrated that employees at a large urban hospital who purchased the least healthy food in its cafeteria were more likely to have an unhealthy diet outside of work, be overweight and/or obese, and have risk factors for diabetes and cardiovascular disease, compared to employees who made healthier purchases.
A Fred Hutchinson Cancer Research Center-led study has found that two organochlorine pesticides are associated with an increased risk of endometriosis, a condition that affects up to 10 percent of reproductive-age women.
Pain is a common symptom of cancer and side effect of cancer treatment, and treating cancer-related pain is often a challenge for health care providers.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Andrew B Beaver, MD 3 Cooper Plz, Suite 408, Camden, NJ 08103-1438 Ph: (856) 968-3670 | Dr Andrew B Beaver, MD 3 Cooper Plz, Suite 408, Camden, NJ 08103-1438 Ph: (856) 968-3670 |
News Archive
CytoDyn Inc. ("CytoDyn") (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, today announced that CytoDyn Chief Medical Officer David Feigal, M.D., has submitted a revised protocol to the U.S. Food and Drug Administration relating to an upcoming Phase IIb clinical trial of PRO 140, CytoDyn's leading product under development as a treatment for Human Immunodeficiency Virus (HIV) infection.
A new study in the American Journal of Preventive Medicine, published by Elsevier, demonstrated that employees at a large urban hospital who purchased the least healthy food in its cafeteria were more likely to have an unhealthy diet outside of work, be overweight and/or obese, and have risk factors for diabetes and cardiovascular disease, compared to employees who made healthier purchases.
A Fred Hutchinson Cancer Research Center-led study has found that two organochlorine pesticides are associated with an increased risk of endometriosis, a condition that affects up to 10 percent of reproductive-age women.
Pain is a common symptom of cancer and side effect of cancer treatment, and treating cancer-related pain is often a challenge for health care providers.
› Verified 4 days ago
Dr. Henry Joseph Dolch Jr., D.O. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 3 Cooper Plz Rm 403, Camden, NJ 08103 Phone: 856-342-2439 | |
David H. Clements, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 3 Cooper Plaza, Suite 408, Camden, NJ 08103 Phone: 856-968-7845 Fax: 856-968-8288 | |
Dr. Stuart L Gordon, M.D. Orthopedic Surgery Medicare: Medicare Enrolled Practice Location: 3 Cooper Plz, Suite 502, Camden, NJ 08103 Phone: 856-968-7433 Fax: 856-968-8499 | |
Dr. Matthew Theys Kleiner, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 3 Cooper Plz Rm 104, Camden, NJ 08103 Phone: 856-968-6895 | |
Kudret Iman Usmani, MD Orthopedic Surgery Medicare: Medicare Enrolled Practice Location: 1 Cooper Plz, Camden, NJ 08103 Phone: 800-826-6737 | |
Michael J Kimball, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 1 Cooper Plz, Camden, NJ 08103 Phone: 856-342-3159 |